Skip to main content

Table 1 Correlations between the down-regulation of EGFL8 and clinico- pathological features of hepatocellular carcinoma

From: Down-regulation of EGFL8 regulates migration, invasion and apoptosis of hepatocellular carcinoma through activating Notch signaling pathway

  Down-regulation of Egfl8  
Clinicopathological features Variables n Positive Negative P-Value
Gender Male 80 60 20 0.828
Female 22 16 6
Age ≥ 65 years 44 34 10 0.650
<  65 years 58 42 16
Etiology HBV infection 71 54 17 0.154
HCV infection 9 6 3
Other or rare cause 22 12 10
Liver cirrhosis Presence 65 51 14 0.245
Absence 37 25 12
Serum AFP level ≥ 20 μg/L 60 43 17 0.494
<  20 μg/L 42 33 9
Maximal tumor size ≥ 5 cm 63 50 13 0.168
<  5 cm 39 26 13
Edmondson-Steiner grade I – II 71 54 17 0.626
III – IV 31 22 9
Capsular formation Presence 57 39 18 0.169
Absence 45 37 8
Tumor nodule number Solitary 61 40 21 0.019*
Multiple (≥2) 41 36 5
Vein invasion Presence 46 40 6 0.012*
Absence 56 36 20
TNM stagea I – II 52 34 18 0.031*
III – IV 50 42 8
  1. The P-values were obtained from Chi-square test or Fisher’s exact test and all tests were two-sided. aTNM classification is according to 8th Edition of the AJCC (American Joint Committee on Cancer) Cancer Staging Manual. *, P < 0.05. EGFL8:epidermal growth factor-like domain; AFP α-fetoprotein, HBV Hepatitis B virus, HCV Hepatitis C virus